Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Clinical trial NCT03783078 · COMPLETED

Trial details

NCT number: NCT03783078
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Merkel Cell Carcinoma

Start date: 2019-02-25
Primary completion: 2022-02-15
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.